<p>/PRNewswire/ -- Azenta, Inc.（纳斯达克代码：AZTA）今天宣布，其子公司 Azenta Germany GmbH 已与 THELEMA S.À R.L.签署了一项具有约束力的协议，以 6300 万美元的价格出售 Azenta 的 B Medical Systems 业务。该交易预计将在 2026 年 3 月 31 日或之前完成。</p>
<p>“出售 B Medical Systems 的协议标志着简化产品组合、优先考虑我们具有最高战略影响力的核心能力的重要一步，” 首席执行官 John Marotta 表示。“此次出售的收益将用于增强公司实力，并为我们的股东创造长期的盈利价值。”</p>
<p>B Medical Systems 是一家总部位于卢森堡的全球医疗制冷设备制造和分销商。</p>
<p>William Blair 担任此次交易的独家财务顾问，Taylor Wessing 担任 Azenta 的法律顾问。</p>
<p><strong>关于 Azenta 生命科学</strong></p>
<p>Azenta, Inc.（纳斯达克代码：AZTA）是全球领先的生命科学解决方案提供商，帮助全球生命科学组织更快地将具有影响力的突破和疗法推向市场。Azenta 提供全面可靠的冷链样本管理解决方案和多组学服务，涵盖药物开发、临床研究和先进细胞疗法等领域，服务于全球顶尖的制药、生物技术、学术和医疗机构。我们的全球团队通过行业领先的品牌（包括 GENEWIZ、FluidX、Ziath、4titude、Limfinity、Freezer Pro 和 Barkey）提供和支持这些产品和服务。</p>
<p>Azenta 总部位于马萨诸塞州伯灵顿，在北美、欧洲和亚洲开展业务。欲了解更多信息，请访问 www.azenta.com。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含前瞻性声明，包括交易的预计完成日期。这些声明涉及风险和不确定性，可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。尽管公司的前瞻性声明反映了管理层的善意判断，但这些声明仅基于公司当前已知的事实和因素。因此，您被警告不要依赖这些前瞻性声明。本新闻稿中以 8-K 表格发布的任何前瞻性声明仅在其发布之日有效。除非法律要求，否则公司不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
<p>投资者联系方式：</p>
<p>Yvonne Perron</p>
<p>财务规划与分析副总裁及投资者关系负责人</p>
<p>ir@azenta.com</p>
<p>Maria Isabel Cuartas</p>
<p>投资者关系经理</p>
<p>ir@azenta.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg"/></p>
<p>来源：Azenta</p>

AZTA

<p>Azenta, Inc. 已签署一项最终协议，将其 B Medical Systems 业务以 6300 万美元的价格出售给 THELEMA S.À R.L.，预计交易将在 2026 年 3 月 31 日之前完成。首席执行官 John Marotta 表示，此次出售将有助于简化公司的产品组合，并专注于核心能力。出售所得将用于增强公司的实力并提升股东价值。William Blair 担任此次交易的财务顾问</p>

<p>, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The transaction is expected to close on or before March 31, 2026.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Azenta, Inc.（纳斯达克代码：AZTA）今天宣布，其子公司 Azenta Germany GmbH 已与 THELEMA S.À R.L.签署了一项具有约束力的协议，以 6300 万美元的价格出售 Azenta 的 B Medical Systems 业务。该交易预计将在 2026 年 3 月 31 日或之前完成。</p>
</div><p>&#34;The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact,&#34; said John Marotta, President and CEO. &#34;The proceeds from this sale will be deployed to strengthen the company and drive long-term profitable value creation for our shareholders.&#34;</p>
<div class="lb-trans"><p>“出售 B Medical Systems 的协议标志着简化产品组合、优先考虑我们具有最高战略影响力的核心能力的重要一步，” 首席执行官 John Marotta 表示。“此次出售的收益将用于增强公司实力，并为我们的股东创造长期的盈利价值。”</p>
</div><p>B Medical Systems is a global manufacturer and distributor of medical refrigeration devices based in Luxembourg.</p>
<div class="lb-trans"><p>B Medical Systems 是一家总部位于卢森堡的全球医疗制冷设备制造和分销商。</p>
</div><p>William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel to Azenta for this transaction.</p>
<div class="lb-trans"><p>William Blair 担任此次交易的独家财务顾问，Taylor Wessing 担任 Azenta 的法律顾问。</p>
</div><p><strong>About Azenta Life Sciences</strong></p>
<div class="lb-trans"><p><strong>关于 Azenta 生命科学</strong></p>
</div><p>Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.</p>
<div class="lb-trans"><p>Azenta, Inc.（纳斯达克代码：AZTA）是全球领先的生命科学解决方案提供商，帮助全球生命科学组织更快地将具有影响力的突破和疗法推向市场。Azenta 提供全面可靠的冷链样本管理解决方案和多组学服务，涵盖药物开发、临床研究和先进细胞疗法等领域，服务于全球顶尖的制药、生物技术、学术和医疗机构。我们的全球团队通过行业领先的品牌（包括 GENEWIZ、FluidX、Ziath、4titude、Limfinity、Freezer Pro 和 Barkey）提供和支持这些产品和服务。</p>
</div><p>Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.</p>
<div class="lb-trans"><p>Azenta 总部位于马萨诸塞州伯灵顿，在北美、欧洲和亚洲开展业务。欲了解更多信息，请访问 www.azenta.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release contains forward-looking statements, including the expected closing date for the transaction. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括交易的预计完成日期。这些声明涉及风险和不确定性，可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。尽管公司的前瞻性声明反映了管理层的善意判断，但这些声明仅基于公司当前已知的事实和因素。因此，您被警告不要依赖这些前瞻性声明。本新闻稿中以 8-K 表格发布的任何前瞻性声明仅在其发布之日有效。除非法律要求，否则公司不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
</div><p>INVESTOR CONTACTS:</p>
<div class="lb-trans"><p>投资者联系方式：</p>
</div><p>Yvonne Perron</p>
<div class="lb-trans"><p>Yvonne Perron</p>
</div><p>Vice President, Financial Planning &amp; Analysis, and Investor Relations</p>
<div class="lb-trans"><p>财务规划与分析副总裁及投资者关系负责人</p>
</div><p>ir@azenta.com</p>
<div class="lb-trans"><p>ir@azenta.com</p>
</div><p>Maria Isabel Cuartas</p>
<div class="lb-trans"><p>Maria Isabel Cuartas</p>
</div><p>Manager, Investor Relations</p>
<div class="lb-trans"><p>投资者关系经理</p>
</div><p>ir@azenta.com</p>
<div class="lb-trans"><p>ir@azenta.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg" alt="" original-src="https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg"/></p>
<p>SOURCE Azenta</p>
<div class="lb-trans"><p>来源：Azenta</p>
</div>

Azenta 与 THELEMA S.À R.L.签署最终协议，出售其 B 医疗系统业务 | AZTA 股票新闻